Fig. 1From: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015Survival curves. a Progression-free survival (PFS) and (b) overall survival (OS). At a median follow-up time of 12.2 months (range, 3.8–15.4 months), the median PFS and OS times were 5.4 and 13.6 months, respectivelyBack to article page